Warner Chilcott Reports Operating Results for the Quarter and Year ended Decembe...(uthorized generic version ofESTROSTEP FE...)

Date:2/29/2008

uthorized generic version of ESTROSTEP FE. OVCON net sales declined $1.9 million, or 37.2%, in the quarter ended December 31, 2007 compared with the prior year quarter. The decline in OVCON revenues was primarily due to the introduction of generic versions of OVCON 35 beginning in late October 2006, which led to an 83.3% decline in filled prescriptions in the quarter ended December 31, 2007 compared to the prior year quarter. This decline was partially offset by price increases.

Sales of our dermatology products increased $12.6 million, or 14.3%, in the quarter ended December 31, 2007 compared to the prior year quarter, primarily due to a $7.5 million increase in TACLONEX sales. Filled prescriptions for TACLONEX increased 33.8% compared to the prior year quarter. Sales of DORYX increased $4.5 million, or 16.4%, in the quarter ended December 31, 2007, compared with the prior year quarter due to increased demand and higher average selling prices. DORYX prescriptions had been declining through the first half of 2007. In January 2007, we took steps to increase our Dermatology sales force's emphasis on DORYX and those changes resulted in filled prescriptions of DORYX increasing 4.8% in the quarter ended December 31, 2007, compared to the prior year quarter. Sales of DOVONEX increased $0.6 million, or 1.6%, in the quarter ended December 31, 2007 compared with the prior year quarter as price increases more than offset a 23.0% decline in filled prescriptions.

Sales of our hormone therapy products increased $2.5 million, or 6.4%, in the quarter ended December 31, 2007, compared with the prior year quarter. FEMHRT filled prescriptions were down 12.9% in the quarter ended December 31, 2007, compared with the prior year quarter. The impact of this decrease was partially offset by higher selling prices. Sales of ESTRACE CREAM increased due to higher average selling prices, although filled prescriptions were flat in the quarter ended December 31, 2007 compared with
'/>"/>

SOURCE Warner Chilcott Limited Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Related biology technology :

1. Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results
2. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
3. Warner Chilcott Announces Earnings Release Date and Conference Call for Third Quarter 2007 Financial Results
4. Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent
5. Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
6. Cepheid Reports Fourth Quarter and Full Year 2007 Results
7. Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results
8. US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
9. Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
10. Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results
11. eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results